# EDGAR Filing Document

**Accession Number:** 0001834105
**File Stem:** 0001493152-25-021066
**Filing Date:** 2025-11
**Character Count:** 6530
**Document Hash:** fee38bd411528f1373768c6f1add0d5e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-021066.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001493152-25-021066

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251105

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IMPACT BIOMEDICAL INC.
- **CENTRAL INDEX KEY:** 0001834105
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 853926944
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42212
- **FILM NUMBER:** 251458239

**BUSINESS ADDRESS:**
- **STREET 1:** 1400 BROADFIELD BLVD.
- **STREET 2:** SUITE 130
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77084
- **BUSINESS PHONE:** 585 232 1500

**MAIL ADDRESS:**
- **STREET 1:** 1400 BROADFIELD BLVD.
- **STREET 2:** SUITE 130
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77084

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 5, 2025**

**<u>IMPACT BIOMEDICAL INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-42212** | **85-3926944** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **1400 Broadfield Blvd., Suite 130,**<br> **Houston, TX**  | **77084** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

Registrant's telephone number, including area code: **(585) 325-3610**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Ticker symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | IBO | The NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On November 5, 2025, Impact Biomedical Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting"). A total of 64,328,010 shares of common stock of the Company, representing 88.50% of the aggregate shares outstanding and eligible to vote on September 8, 2025, the record date for the Meeting, and constituting a quorum, were represented in person or by valid proxies at the Meeting.

The stockholders approved the election of Frank D. Heuszel; Elise Brownell; Melissa Sims; Castel Hibbert; David Keene; Christian Zimmerman; Jason Grady and Chan Heng Fai Ambrose to serve as directors of the Company until the next Annual Meeting of the shareholders.

The stockholders ratified the appointment of Grassi & Co. Certified Public Accountants, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

The stockholders approved, on an advisory basis, the compensation of the named executive officers.

The final voting results on these matters were as follows:

***1. Approval of the election of Frank D. Heuszel; Elise Brownell; Melissa Sims; Castel Hibbert; David Keene; Christian Zimmerman; Jason Grady and Chan Heng Fai Ambrose to serve as directors of the Company until the next Annual Meeting of the shareholders:***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **FOR** | **AGAINST** | **WITHHELD** | **BROKER<br> NON-VOTES** |
| Frank D. Heuszel | 61565626 | 54136 | 5487 | 2702761 |
| Elise Brownell | 61535306 | 74945 | 14997 | 2702761 |
| Melissa Sims | 61496912 | 112291 | 16046 | 2702761 |
| Castell Hibbert | 61564380 | 45380 | 15489 | 2702761 |
| David Keene | 61536534 | 73768 | 14947 | 2702761 |
| Christian Zimmerman | 61566321 | 43460 | 15468 | 2702761 |
| Jason Grady | 61566251 | 52677 | 6321 | 2702761 |
| Chan Heng Fai Ambrose | 61505698 | 113631 | 5920 | 2702761 |

---

***2. Ratification of the appointment of Grassi & Co. Certified Public Accountants, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **FOR** | **FOR** | **AGAINST** | **AGAINST** | **ABSTAIN** | **ABSTAIN** |
|  | 64126924 |  | 174317 |  | 26769 |

---

***3. Approval on an advisory basis of the compensation of the named executive officers:***

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **FOR** | **FOR** | **AGAINST** | **AGAINST** | **ABSTAIN** | **ABSTAIN** | **BROKER NON-VOTES** | **BROKER NON-VOTES** |
|  | 61512770 |  | 107684 |  | 4795 |  | 2702761 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IMPACT BIOMEDICAL INC.** | **IMPACT BIOMEDICAL INC.** |
| Date: November 6, 2025 | By: | */s/ Frank D. Heuszel* |
|  | Name: | Frank D. Heuszel |
|  | Title: | Chief Executive Officer |

---